CDKN1A and atherosclerosis: Based on these data showing learning impairment and increased p21 expression with atherosclerosis progression, male and female ATX mice were treated with the senolytic ABT-263 (Navitoclax) using 2 time frames: a preventive treatment in young mice from 3- to 6-mo, or a curative treatment in middle-aged mice from 9- to 12-mo was applied, to respectively prevent or delay VCI in male and female ATX mice.